TY - JOUR
T1 - A phase i trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer
AU - Wada, Hitoshi
AU - Nemoto, Kenji
AU - Nomiya, Takuma
AU - Murakami, Misako
AU - Suzuki, Motohisa
AU - Kuroda, Yuuki
AU - Ichikawa, Mayumi
AU - Ota, Ibuki
AU - Hagiwara, Yasuhito
AU - Ariga, Hisanori
AU - Takeda, Ken
AU - Takai, Kenji
AU - Fujimoto, Keisuke
AU - Kenjo, Masahiro
AU - Ogawa, Kazuhiko
PY - 2013/4
Y1 - 2013/4
N2 - Background: The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of S-1. Methods: We enrolled 9 patients between April 2005 and March 2009. Radiotherapy (total dose, 60 Gy in 30 fractions) was given to the gross local recurrent tumor and pelvic nodal metastases using three-dimensional radiotherapy planning. We administered oral S-1 twice a day on days 1-14 and 22-35 during radiotherapy. The dose of S-1 was initially 60 mg/m2/day and was increased to determine the MTD and RD for this regimen. Results: DLT appeared at dose level 2 (70 mg/m2/day) in 2 patients, who experienced grade 3 enterocolitis and consequently required suspension of S-1 administration for longer than 2 weeks. Hematological toxicity was mild and reversible. At the initial evaluation, complete regression and partial regression were seen in 1 patient (11%) and 2 patients (22%), respectively. Conclusion: This phase I trial of S-1 chemotherapy with pelvic radiotherapy for locally recurrent rectal cancer revealed that the MTD for S-1 was 70 mg/m2/day and the RD was 60 mg/m2/day.
AB - Background: The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of S-1. Methods: We enrolled 9 patients between April 2005 and March 2009. Radiotherapy (total dose, 60 Gy in 30 fractions) was given to the gross local recurrent tumor and pelvic nodal metastases using three-dimensional radiotherapy planning. We administered oral S-1 twice a day on days 1-14 and 22-35 during radiotherapy. The dose of S-1 was initially 60 mg/m2/day and was increased to determine the MTD and RD for this regimen. Results: DLT appeared at dose level 2 (70 mg/m2/day) in 2 patients, who experienced grade 3 enterocolitis and consequently required suspension of S-1 administration for longer than 2 weeks. Hematological toxicity was mild and reversible. At the initial evaluation, complete regression and partial regression were seen in 1 patient (11%) and 2 patients (22%), respectively. Conclusion: This phase I trial of S-1 chemotherapy with pelvic radiotherapy for locally recurrent rectal cancer revealed that the MTD for S-1 was 70 mg/m2/day and the RD was 60 mg/m2/day.
KW - Chemotherapy
KW - Locally recurrent rectal cancer
KW - Radiotherapy
KW - S-1
UR - http://www.scopus.com/inward/record.url?scp=84880917920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880917920&partnerID=8YFLogxK
U2 - 10.1007/s10147-012-0375-y
DO - 10.1007/s10147-012-0375-y
M3 - Article
C2 - 22318782
AN - SCOPUS:84880917920
VL - 18
SP - 273
EP - 278
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 2
ER -